Mylan, Pfizer Say EpiPen Antitrust Suits Don't Need MDL

Law360, New York (May 18, 2017, 1:59 PM EDT) -- Mylan NV and Pfizer Inc. on Wednesday each urged the Judicial Panel on Multidistrict Litigation not to consolidate antitrust litigation against the drugmakers, arguing the majority of cases are already working together in Kansas to make the litigation work, so the move is unnecessary.

However, if the panel finds MDL is fitting, Mylan and Pfizer said it should be done in Kansas where the bulk of the litigation is already taking place, not New Jersey as the plaintiffs bringing the consolidation motion requested. Eight potential class...
To view the full article, register now.